Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-FGFR4 CAR T cells

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting human fibroblast growth factor receptor 4 (FGFR4), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-FGFR4 CAR T cells recognize and induce selective toxicity in FGFR4-expressing tumor cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous anti-FGFR4 CAR-T cells autologous FGFR4-CAR T cells

autologous anti-FGFR4 CAR T cells

Search NCI's Drug Dictionary